CONNECT WITH US
HealthTech

HealthTech

Experimental mRNA therapy promotes repair after heart attack damage

Medical Xpress logo

Published on

Add as a preferred source on Google
Experimental mRNA therapy promotes repair after heart attack damage

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Scientists have developed a treatment that 'reawakens' heart muscle cells so they start to divide and help repair damaged muscle.

In a study in mice, this produced a stronger heartbeat and increased the amount of blood pumped through the heart with each heartbeat by around 10%, compared with mice that received a mock treatment, following a heart attack.

While this is not a full cure, even small improvements to heart function have been linked to lower mortality in patients and a better ability to carry out daily activities.

The treatment uses mRNA therapy to temporarily activate two proteins inside heart cells, called Myc and Cyclin T1, promoting repair of heart tissue.

This has the potential in the future to be used to treat patients with heart failure. Around 200,000 people in the U.K. are diagnosed with heart failure each year, and while current treatments can reduce symptoms and slow the progression of heart disease, they can't regenerate heart muscle that has already been lost.

"These are really exciting results. There's no cure for heart failure, and our treatment could potentially have a meaningful impact on the quality of life of millions of people around the world," said Dr. Catherine Wilson, associate professor at the University of Cambridge's Department of Pharmacology and Gurdon Institute, co-senior author of the study.

She added, "We're not just treating the symptoms of heart failure—this approach could help the heart to repair itself."


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.